About: Neuroprotective Role of Oral Vitamin D Supplementation on Consciousness and Inflammatory Biomarkers in Determining Severity Outcome in Acute Traumatic Brain Injury Patients: A Double-Blind Randomized Clinical Trial

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Neuroprotective Role of Oral Vitamin D Supplementation on Consciousness and Inflammatory Biomarkers in Determining Severity Outcome in Acute Traumatic Brain Injury Patients: A Double-Blind Randomized Clinical Trial Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Neuroprotective Role of Oral Vitamin D Supplementation on Consciousness and Inflammatory Biomarkers in Determining Severity Outcome in Acute Traumatic Brain Injury Patients: A Double-Blind Randomized Clinical Trial
Creator	Kumar, · Bisht, Akansha Choudhary, Ajay Khurana, Lipika Kumar, Vijender Sharma, Neera Sharma, Shallu Sharma, Swapnil
Source	PMC
abstract	BACKGROUND AND OBJECTIVE: Early management of traumatic brain injury (TBI) is essential. We aimed to evaluate the efficacy of vitamin D over early clinical outcome and serum cytokine levels in patients with moderate to severe brain injury. METHODS: Thirty-five patients with moderate to severe traumatic brain injury who were admitted to the ICU unit were recruited into the study. Subjects were randomly allocated to a treatment regimen comprising either a one-time oral dose of 120,000 IU (two tablets of 60,000 IU each) of vitamin D (n = 20) or 8 mg of saccharide (two tablets of 4 g each) as placebo (n = 15). The main parameters evaluated included duration of mechanical ventilation and ICU stay, Glasgow Coma Scale (GCS) and cytokine levels (interleukin (IL)-6, tumour necrosis factor (TNF)-α, interferon (IFN)-γ, IL-2). RESULTS: The results indicated an improvement in the level of consciousness after 7 days in the vitamin D-treated group compared with placebo. An elevation in GCS score by 3.86 units in the vitamin D-treated group with a 0.19-unit descent in the control group was recorded. Duration of mechanical ventilation was reduced in the vitamin D-treated group compared with the control group (4.7 days vs. 8.2 days, p value 0.0001). A noticeable reduction was recorded in inflammatory biomarkers (cytokines) in the vitamin D-treated group (IL-6 p = 0.08, TNF-α p = 0.02, IL-2 p = 0.36) with notable elevation in IFN-γ (p = 0.65) compared to the control group. CONCLUSION: In the acute phase of moderate to severe traumatic brain injury, vitamin D supplementation plays a vital role and has a favourable effect on the consciousness level of patients. Clinical trial Registry (CTRI) No. CTRI/2019/05/019259.
has issue date	2020-03-14(xsd:dateTime)
bibo:doi	10.1007/s40261-020-00896-5
bibo:pmid	32172522
has license	no-cc
sha1sum (hex)	14e965008442acf421cac9d1610f26fe62c5ab69
schema:url	https://doi.org/10.1007/s40261-020-00896-5
resource representing a document's title	Neuroprotective Role of Oral Vitamin D Supplementation on Consciousness and Inflammatory Biomarkers in Determining Severity Outcome in Acute Traumatic Brain Injury Patients: A Double-Blind Randomized Clinical Trial
has PubMed Central identifier	PMC7224135
has PubMed identifier	32172522
schema:publication	Clin Drug Investig
resource representing a document's body	covid:14e965008442acf421cac9d1610f26fe62c5ab69#body_text
is schema:about of	named entity 'ICU' named entity 'vitamin D' named entity 'study' named entity 'ICU' named entity 'severe' named entity 'Role' named entity 'Neuroprotective' named entity 'Vitamin D' named entity 'TREATMENT REGIMEN' named entity 'interleukin' named entity 'Early' named entity 'early' named entity 'levels' named entity 'IL-2' named entity 'cytokine' named entity 'allocated' named entity 'levels' named entity 'Background' named entity 'Randomized' named entity 'tumour necrosis factor' named entity 'Glasgow Coma Scale' named entity 'cytokine' named entity 'saccharide' named entity 'traumatic brain injury' named entity '60,000' named entity 'Double-Blind' named entity 'Randomized Clinical Trial' named entity 'vitamin' named entity 'IL-6' named entity 'clinical outcome' named entity 'Delhi' named entity 'physiology' named entity 'IL-2' named entity 'secondary injury' named entity 'mechanical ventilation' named entity 'Cytokine' named entity 'inflammatory response' named entity 'biomarkers' named entity 'confounding' named entity 'oxidative stress' named entity 'brain damage' named entity 'oxygen' named entity 'vitamin' named entity 'clinical history' named entity 'vitamin' named entity 'progesterone' named entity 'GCS' named entity 'glatiramer acetate' named entity 'vitamin' named entity 'inflammation' named entity 'Study protocol' named entity 'vitamin' named entity 'mechanical ventilation' named entity 'cytokine' named entity 'neuronal damage' named entity 'pharmacological' named entity 'brain damage' named entity 'IL-6' named entity 'neurodegeneration' named entity 'TBI' named entity 'traumatic event' named entity 'enhancer' named entity 'neurosurgery' named entity 'Experimental evidence' named entity 'IL-6' named entity 'TNF-α' named entity 'haematocrit' named entity 'vitamin' named entity 'vitamin' named entity 'Dr. Ram Manohar Lohia Hospital' named entity 'D group' named entity 'IL-6' named entity 'post-traumatic stress disorder' named entity 'vitamin'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software